After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...
BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...
Source: Getty Images Updated data support the use of perioperative pembrolizumab as part of standard care for patients with high-risk, early TNBC, according to Peter Schmid, MD, PhD. At 5 years ...
The FDA approved the frontline combination of pembrolizumab (Keytruda) and chemotherapy in patients with unresectable advanced or metastatic malignant pleural mesothelioma. This approval is supported ...
Gorila-gorila yang mengobati luka sendiri mungkin menyimpan petunjuk untuk penemuan obat di masa mendatang, kata sejumlah ilmuwan. Para peneliti di Gabon, negara yang terbentang di pesisir barat ...
In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer ...
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting.
Jika berbagai usaha Anda untuk memperbaiki kerontokan gagal terus, ada baiknya konsultasikan ke dokter mengenai pilihan obat rambut rontok sesuai dengan penyebabnya. Minoxidil adalah obat yang ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback